Skip to main content
. Author manuscript; available in PMC: 2015 Sep 1.
Published in final edited form as: Psychopharmacology (Berl). 2014 Jan 31;231(17):3293–3312. doi: 10.1007/s00213-014-3435-3

Figure 4.

Figure 4

Cytometric analysis of the prevention by ent-PREGS (0.25-10 μM) of Aβ25-35-induced B104 cell death: (A) representative Annexin-V-Alexa 488/propidium iodide (PI) double stainings of B104 cells treated with Aβ25-35 peptide ± ent-PREGS (1, 5, 10 μM). The percentages of cells analyzed by flow cytometry in each quadrant under each condition are indicated: lower left, Alexa 488−/PI−, normal intact cells; lower right, Alexa 488+/PI−, early apoptototic cells; upper left, Alexa 488−/PI+, necrotic cells; and upper right, Alexa 488+/PI+, late apoptotic cells. Graphs show the quantification of the percentages of dead cells (B), early apoptotic cells (C), late apoptotic cells (D), and necrotic cells (E). One-way ANOVA: F(11,37) = 14.9, p < 0.001 in (B); F(11,37) = 0.90, p > 0.05 in (C); F(11,37) = 6.39, p < 0.001 in (D); F(11,37) = 2.77, p < 0.01 in (E). * p < 0.05, ** p < 0.01, *** p < 0.001 vs. control cells; ## p < 0.01, ### p < 0.001 vs. Aβ25-35-treated cells; Fisher's PLSD test.